Ann: Mesoblast Phase 3 Chronic Low Back Pain Results, page-142

@Duku, I’m afraid that is how the market feels. MSB has delivered today’s trial update late, and without validation of the results in the form of a partnership. The market has lost its appetite for anything that MSB has to offer. No partnerships = more capital raises, and the scumbag shorters know it. The carrot dangling in front of investors does not longer work without MSB delivering a clear and concise pathway to revenue making commercialisation of their products - so far they are years away. It is sad and in my opinion, the best that shareholders can hope for is for a takeover at $5 dollars.